Monica Ramirez
Acute Care · Miami, FLNPI 1043663735
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 397 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 29.2% of the total. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 397 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$3K
- Boehringer Ingelheim$1K
- Mallinckrodt Hospital Products Inc.$414
- Sanofi$336
- Amgen$291
- plus $1K from 17 others
What the payments were for
- Food & beverage$9,119100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 111 | $2,666 |
| GSK | 125 | $2,587 |
| Boehringer Ingelheim | 58 | $1,468 |
| Mallinckrodt Hospital Products Inc. | 25 | $414 |
| Sanofi | 11 | $336 |
| Amgen | 14 | $291 |
| Verona Pharma, Inc. | 9 | $246 |
| Insmed, Inc. | 10 | $241 |
| Paratek Pharmaceuticals, Inc. | 4 | $187 |
| ANI Pharmaceuticals, Inc. | 5 | $139 |
| Regeneron Healthcare Solutions, Inc. | 5 | $119 |
| Pfizer | 4 | $76 |
| Advanced Respiratory, Inc | 3 | $68 |
| Mylan Specialty L.p. | 3 | $66 |
| Baxter Healthcare | 2 | $48 |
| Boston Scientific | 1 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Viatris Specialty LLC | 1 | $25 |
| Lilly USA, LLC | 1 | $21 |
| Merck | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Genentech USA, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,136 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $76,946 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $39,162 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $9,517 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,991 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,476 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $3,434 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,357 |
| Ventolin HfaAlbuterol Sulfate | 34 | $1,877 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 95 | $1,817 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,757 |
| Azelastine Hcl | 36 | $782 |
| Fluticasone Propionate | 33 | $411 |
| Methylprednisolone | 35 | $231 |
| Montelukast Sodium | 26 | $213 |
| Famotidine | 24 | $148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $2,587 | $90,413142 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,666 | $48,67988 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.
Other acute care in Miami
- Yvette NaranjoMiami$12K
- Yuri CarmonaMiami$10K
- Rosa Canete-YohamMiami$9K
- Julio AcostaMiami$9K
- Uday DasariMiami$7K
- Julissa WilliamsMiami$7K
- Michelle ViteriMiami$6K
- Marie RenoitMiami$6K
- Rebecca JuliaoMiami$5K
- Lissette Gomez-RiosMiami$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.